Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.3.1.900
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 9,276 $ 3,970
Accounts receivable $ 32 122
Marketable securities 1,975
Prepaid and other current assets $ 441 144
Mortgage note receivable, current portion 170 165
Total current assets 9,919 6,376
Property and equipment, net 430 284
Deposits 31 31
Mortgage note receivable, long-term portion 2,354 2,431
In process research and development 146,301 184,966
Goodwill 65,195 65,195
Total Assets 224,230 259,283
Current liabilities:    
Accounts payable and accrued expenses 2,535 693
Derivative liabilities 4,115 8,464
Total current liabilities 6,700 9,157
Long-term liabilities    
Deferred rent 61 62
Deferred tax liability 49,875 65,195
Total long-term liabilities 49,936 65,257
Total liabilities 56,636 $ 74,414
Commitments and contingencies  
Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, issued and outstanding at December 31, 2014, issued in the merger with RFS Pharma, LLC 0 $ 178,218
Stockholders' equity:    
Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 10 and 1,000 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively 0 1
Common stock, $.001 par value; 800,000 and 200,000 shares authorized, 694,396 and 122,494 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively 694 123
Additional paid-in capital 229,456 18,725
Accumulated other comprehensive income, net of tax 0 236
Accumulated deficit (62,556) (12,434)
Total stockholders' equity 167,594 6,651
Total liabilities and stockholders' equity $ 224,230 $ 259,283